MYC and breast carcinoma: We demonstrate that ErbB2 levels determine the relative contributions of CDK4-cyclin D1 and c-Myc pathways, with distinct temporal dynamics and reversibility patterns that have not been previously characterized in the context of ErbB2 heterogeneity within luminal A breast cancer.